

## The pan-Canadian Oncology Drug Review

November 1 2010

Dear Sir/Madam,

As follow-up to my letter of October 18, 2010, I am writing to you today to provide further information about an upcoming pan-Canadian Oncology Drug Review (pCODR) information session.

A newly established evidence-based cancer drug review process, the pCODR is designed to assess the clinical evidence and cost-effectiveness of new cancer drugs, and to use this information to make recommendations to the provinces and territories in guiding their drug funding decisions. The implementation of the pCODR is well underway and the anticipated rollout will begin in early 2011.

As I noted in my first correspondence, our partners in the pCODR collaboration have been working to shape the submission and review process. Many of you provided significant and thoughtful input through the interim JODR, and to further assist in the development of the pCODR and to hear about progress to date, **we are inviting you to an information and input session for patient groups on November 24, 2010** at the Intercontinental Hotel, 225 Front Street West in Toronto, from **10:00 a.m. to noon** in the Grenadier meeting room. For those unable to join in-person, a webinar option will be provided.

The session's objectives are to share information on the pCODR process, gather your input on the nomination and selection process for the pCODR Expert Review Committee – including the proposed criteria for the selection of patient representatives – and to discuss the ways in which the pCODR process can reflect its guiding principles which include fair and transparent governance and cross-jurisdictional collaboration. The contributions of patient advocacy groups have been invaluable in shaping the pCODR process to this point; we hope you will be able to join us, to continue this collaborative effort.

### **Moving Forward**

The role of the pCODR Expert Review Committee (pERC) is to take the clinical and economic information relating to the cancer drug under review, and to formulate a funding recommendation for the provinces and territories. Once the nomination and selection process for that committee has been finalized, which is likely early December, we will be in touch about how and when to submit the names of candidates for the patient representative positions. At that time, we will also be asking for your suggestions on nominations for the pERC Chair.

Please confirm your attendance at the information and input session via e-mail: [rsvp@pcodr.ca](mailto:rsvp@pcodr.ca). Once we have your RSVP, we will send the agenda, as well as information about parking, transit information and webinar details.

We look forward to our continued work together,

Sincerely,



*Mona Sabharwal*  
Executive Director  
pan-Canadian Oncology Drug Review  
1 University Avenue, suite 300  
Toronto, ON M5J2P1  
p: 416-619-5743  
f: 416-915-9224  
e: [mona.sabharwal@pcodr.ca](mailto:mona.sabharwal@pcodr.ca)

cc: pCODR Steering Committee